Low-passage, patient-derived cancer cells (PDCs) offer a biologically relevant platform for translational oncology research. Unlike immortalized cell lines, PDCs retain the genetic, phenotypic and functional heterogeneity of primary tumors, enabling more accurate modelling of disease biology and therapeutic response.

Our collection includes PDCs derived from patients with lung, ovarian and skin cancers, annotated with clinical treatment history and genomic profiling data. Within our collection are PDCs containing well-known alterations such as EML4-ALK translocations, KRAS G12A and G12C mutations, and the BRAF V600E mutation.

Notably, several PDCs harbor clinically relevant mutations that are underrepresented or absent in conventional cancer cell lines, such as:

• Activating mutations, including BRAF G466V (class III) and EGFR exon 20 insertion
• Resistance mutations, including ROS1 G2032R, which confers resistance to first-generation ROS1 inhibitors
• Co-occurring alterations in KEAP1, STK11, CDKN2A and SMARCA4 in a KRAS-mutant background, which are associated with reduced response rates and shorter clinical benefit from KRAS G12C inhibitors

Our PDC models are available for molecular profiling, drug synergy studies and mechanistic cell biology research. Please contact us if you want more information.